ALLIANCE A041702

Primary Category:

Treatment Protocols

Disease Category:

Chronic Lymphocytic Leukemia, Leukemia

Status:

Temporarily Closed

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

NCT#03737981

Eligible for screening study DCP 001

Enrollment to A041702  pre-registration (STEP 0) is temporarily suspended to effective June 14, 2022, at 4:00 PM ET.